Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Subscribe To Our Newsletter & Stay Updated
